Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buserelin + human chorionic gonadotropin
- Development stage
- Phase 4
- Lead developer
- Sanofi
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
A combination therapy used in assisted reproduction and fertility treatments. Buserelin is a synthetic GnRH agonist that initially stimulates and then suppresses gonadotropin release, while human chorionic gonadotropin (hCG) mimics LH action to trigger final oocyte maturation and ovulation. This combination is used in IVF protocols where buserelin prevents premature LH surge and hCG induces ovulation at the optimal time.
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on buserelin + human chorionic gonadotropin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buserelin + human chorionic gonadotropin.